Umecrine Cognition AB Feed

Filter

År

Typ

Språk

Rensa

2025-07-14 11:00:00 Umecrine Cognition raises SEK 24,6 million for the ongoing clinical Phase 1b/2a study of golexanolone

2025-05-26 08:45:00 Umecrine Cognition resumes patient inclusion in its clinical Phase I/IIa study of golexanolone in primary biliary cholangitis

2025-05-20 08:45:00 Notice to attend the Annual General Meeting in Umecrine Cognition AB

2025-05-07 08:45:00 Umecrine Cognition to present a novel clinically validated symptom severity scale in Primary Biliary Cholangitis at EASL 2025

2025-05-05 08:45:00 Umecrine Cognition receives a grant from The Michael J. Fox Foundation to support preclinical evaluation of golexanolone in Parkinson’s disease

2025-04-07 08:45:00 Umecrine Cognition attends the International PBC Summit 2025

2025-04-01 13:00:00 Umecrine Cognition appoints Viktor Drvota as new CEO

2025-04-01 08:45:00 Umecrine Cognition presents nonclinical data at AD/PD™ 2025 showing that golexanolone reverses dopamine loss and sustains improvements of Parkinsonian symptoms

2025-03-18 14:45:00 Umecrine Cognition provides update on the Phase 1b/2a clinical study of golexanolone

2025-03-17 08:45:00 Umecrine Cognition will attend BIO-Europe Spring® 2025 in Milan

2025-01-13 08:45:00 Umecrine Cognition attends the 43rd Annual JP Morgan Healthcare Conference

2024-12-19 08:45:00 Umecrine Cognition raises MSEK 23,8 to the ongoing clinical Phase 1b/2 study of golexanolone

2024-11-18 08:45:00 Umecrine Cognition presents positive interim data from ongoing Phase 1b/2a study with golexanolone at the AASLD Liver Meeting in San Diego

2024-10-17 08:45:00 Umecrine Cognition attends INBC 2024 to present new preclinical data showing conserved dopamine signaling in Parkinson’s disease

2024-07-10 08:45:00 Umecrine Cognition raises MSEK 28.3 for the ongoing clinical development of golexanolone

2024-06-28 08:45:00 Umecrine Cognition publishes new nonclinical data for golexanolone in Parkinson’s disease that will be presented at the FENS Forum 2024

2024-06-03 08:45:00 Umecrine Cognition attends BIO 2024 in San Diego

2024-05-08 08:45:00 Umecrine Cognition’s Phase 2 study of golexanolone in Primary Biliary Cholangitis has randomized its first two patients

2024-04-16 08:45:00 Umecrine Cognition publishes scientific review on the role of endogenous neurosteroids in neuroinflammation and their potential therapeutic effect

2024-03-22 08:45:00 Umecrine Cognition’s Phase 1b/2 study of golexanolone in Primary Biliary Cholangitis progresses to Part B following positive safety review

2024-03-18 08:45:00 Umecrine Cognition will attend BIO-Europe Spring® 2024 in Barcelona

2024-03-15 09:00:00 Scientific review of golaxonolone’s therapeutic potential on symptoms arising from neuroinflammation published in Frontiers in Pharmacology

2024-03-06 08:45:00 Umecrine Cognition presents nonclinical data at AD/PD™ 2024 further elucidating golexanolone’s mode-of-action in Parkinson’s disease

2024-01-08 08:45:00 Umecrine Cognition attends the JP Morgan 42nd Annual Healthcare Conference 2024 in San Francisco

2023-11-28 10:30:00 Umecrine Cognition presents preclinical results showing significant decreases in PBC-like symptomology and neuroinflammation

2023-11-17 08:45:00 Umecrine Cognition raises further funding for the clinical development of golexanolone

2023-07-05 08:45:00 Umecrine Cognition presents data at World Parkinson Congress showing positive effects of golexanolone in a preclinical model of Parkinson’s disease

2023-06-07 11:50:00 Umecrine Cognition presents new preclinical data that elucidates the mechanism-of-action of golexanolone in cholestatic liver disease

2023-05-17 08:45:00 Notice to attend the Annual General Meeting in Umecrine Cognition AB

2023-04-17 08:45:00 First patient included in Umecrine Cognition’s clinical Phase 2 study of golexanolone in primary biliary cholangitis

2023-03-28 08:45:00 Umecrine Cognition secures additional funding to progress its drug development projects

2023-01-17 08:45:00 Umecrine Cognition announces Orphan Drug Designation granted by FDA for golexanolone

2023-01-09 08:45:00 Umecrine Cognition will attend the JP Morgan 41st Annual Healthcare Conference 2023 in San Francisco

2023-01-03 08:45:00 Umecrine Cognition presents data showing improved symptoms in a model of Parkinson’s disease following treatment with golexanolone

2022-09-28 08:31:00 Umecrine Cognition presents data showing reversal of fatigue in a model of PBC following treatment with golexanolone

2022-09-14 11:00:00 Umecrine Cognition secures funding ahead of Phase 2 study of golexanolone in patients with primary biliary cholangitis

2022-08-10 17:31:00 Umecrine Cognition announces the recruitment of Anders Karlsson as new CEO

2022-07-07 12:00:00 Notice to attend Extraordinary General Meeting in Umecrine Cognition AB

2022-05-19 08:00:00 Umecrine Cognition submits application for Phase 2 clinical trial of golexanolone

2022-05-18 09:45:00 Notice to attend the Annual General Meeting in Umecrine Cognition AB

2022-03-14 07:59:00 Umecrine Cognition completes successful pre-IND meeting with FDA

2022-02-21 07:00:00 Umecrine Cognition to present preclinical results showing beneficial effects of golexanolone on neuroinflammation and movement dysfunction

2022-01-10 09:00:00 Umecrine Cognition presents data showing a reduction of neuroinflammation following treatment with golexanolone

2021-11-03 08:00:00 Umecrine Cognition presents data supporting a new predictive biomarker in patients with primary biliary cholangitis at the AASLD International Liver Meeting 2021

2021-10-18 14:00:00 Umecrine Cognition enters collaboration with University College London to increase insights around golexanolone

2021-10-06 13:00:00 Umecrine Cognition to present at two scientific conferences on the importance of neurosteroids in cognitive dysfunction associated with liver disease

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Umecrine Cognition AB

Prenumeration

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden